The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal Cancer
|
|---|---|
| Published in |
Frontiers in oncology, June 2018
|
| DOI | 10.3389/fonc.2018.00214 |
| Pubmed ID | |
| Authors |
Florinda Meléndez-Rodríguez, Olga Roche, Ricardo Sanchez-Prieto, Julian Aragones |
| Abstract |
The most common type of the renal cancers detected in humans is clear cell renal cell carcinomas (ccRCCs). These tumors are usually initiated by biallelic gene inactivation of the Von Hippel-Lindau (VHL) factor in the renal epithelium, which deregulates the hypoxia-inducible factors (HIFs) HIF1α and HIF2α, and provokes their constitutive activation irrespective of the cellular oxygen availability. While HIF1α can act as a ccRCC tumor suppressor, HIF2α has emerged as the key HIF isoform that is essential for ccRCC tumor progression. Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF2α can efficiently combat ccRCC growth. In this review, we discuss the molecular basis underlying the oncogenic potential of HIF2α in ccRCC by focusing on those pathways primarily controlled by HIF2α that are thought to influence the progression of these tumors. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 16% |
| Student > Ph. D. Student | 7 | 14% |
| Student > Master | 6 | 12% |
| Student > Doctoral Student | 3 | 6% |
| Student > Bachelor | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 22 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 16% |
| Agricultural and Biological Sciences | 7 | 14% |
| Biochemistry, Genetics and Molecular Biology | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 24 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2020.
All research outputs
#2,532,991
of 26,312,176 outputs
Outputs from Frontiers in oncology
#593
of 22,970 outputs
Outputs of similar age
#49,193
of 345,404 outputs
Outputs of similar age from Frontiers in oncology
#15
of 144 outputs
Altmetric has tracked 26,312,176 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,970 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,404 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 144 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.